As a biotechnology patent attorney, Gary drafts and prosecutes patent applications for a broad range of life sciences inventions and develops intellectual property strategies for university, non-profit, start-up, and mid- and large-cap bio/pharma clients in the life sciences and agricultural industries. Gary also formulates freedom-to-operate, non-infringement and invalidity opinions and performs intellectual property due diligence reviews. His areas of technological expertise include molecular and cell biology, biochemistry, virology, cell biology, immunology, nanotechnology, and personalized medicine.
Gary's scientific experience includes post-doctoral research on the molecular mechanisms of signal transduction at the Fred Hutchinson Cancer Research Center in Seattle and graduate research at the University of North Carolina in Chapel Hill. His Ph.D. in biochemistry and biophysics was awarded for his research on "Structure-Function Studies on Uvra: An Escherichia coli DNA Repair Protein," which was performed in the laboratory of Aziz Sancar, recipient of 2015 Nobel Prize in Chemistry. Prior to attending graduate school, Dr. Myles worked in the Hepatitis/HIV division at Abbott Laboratories, took graduate coursework in chemical engineering at the University of Michigan in Ann Arbor, and obtained a B.S. in biochemistry from the University of Illinois in Urbana/Champaign.
Gary is an adjunct professor of law at Seattle University, where he teaches Biotechnology and the Law, and is an adjunct professor and Law, Technology, and Arts Fellow at the University of Washington, where he teaches Advanced Patent Law. Gary obtained his J.D. from the University of Washington and is admitted to the Washington State Bar, District Court for the Western District of Washington, and United States Patent and Trademark Office.